In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


This content is currently on FREE ACCESS, enjoy another 101 days of free consultation

 

Trimetazidine and nicorandil decrease the increment of serum creatinine in patients with normal or slightly decreased renal function after undergoing elective percutaneous coronary intervention

Session Poster Session 7

Speaker Fengshuang An

Congress : ESC Congress 2019

  • Topic : interventional cardiology and cardiovascular surgery
  • Sub-topic : Coronary Intervention: Complications
  • Session type : Poster Session
  • FP Number : P6532

Authors : X Li (Jinan,CN), X Wang (Jinan,CN), D Liu (Jinan,CN), M Zhang (Jinan,CN), M Liu (Jinan,CN), F An (Jinan,CN)

Authors:
X Li1 , X Wang1 , D Liu1 , M Zhang1 , M Liu1 , F An1 , 1Qi-Lu Hospital of Shandong University School of Medicine, The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education - Jinan - China ,

Citation:

Background: Contrast-induced nephropathy (CIN) is a serious complication of percutaneous coronary intervention which can cause serious adverse outcomes. There is still no effective treatment for it.

Aims To evaluate and compare the protective effect of trimetazidine and nicorandil on renal function in patients undergoing percutaneous coronary intervention.with estimated glomerular filtration (eGFR) > 60 ml/min / 1.7 m2.

Method: 161 patients who met the inclusion criteria were recruited and divided into control group (n=41), trimetazidine group (n=40), nicorandil group (n=40) and trimetazidine combined with nicorandil group (n=40). Both TMZ and nicorandil were administered orally 72 hours before and 48 hours after the procedure. All patients in the four groups were given intravenous saline (0.9%) at a rate of 1 ml/kg/h 6 hours before and 12 hours after the procedure. Serum creatinine (SCr), GFR were measured before and 48 hours after the procedure. An increase of 44mmol/L (0.5mg/dL) in SCr or 25% higher than basal levels at 48 hours after administered iodinated CM was diagnosed as CIN.

Results: (1) The baseline characteristics of the four groups were similar. (2) The SCr levels increased in control group (baseline 73.07±15.69 VS. after PCI 91.71±23.10 mmol/L), TMZ group (baseline 71.90±17.30 VS. after PCI 82.00±17.19 mmol/L), nicorandil group (baseline 72.23±15.95 VS. after PCI 81.45±18.30 mmol/L)and TMZ plus nicorandil group (baseline 71.13±13.50 VS. after PCI 73.35±12.64 mmol/L) at 48 hours after the procedure, all p values < 0.05. (3) The increment of SCr after PCI in control group (?Scr=18.63±9.21 mmol/L) is higher than TMZ group (?Scr=10.10±5.62 mmol/L) and nicorandil group (?Scr=9.23±5.60mmol/L), and is higher than TMZ plus nicorandil group (?Scr=2.23±1.42 mmol/L), all p values < 0.001. There was no statistical difference of increment of SCr between TMZ group and nicorandil group. (4) Contrast-induced nephropathy developed in 14.6% (6/41) in control group, 2.5%(1/40) in TMZ group and 2.5%(1/40) in nicorandil group (p<0.05), none in TMZ plus nicorandil group.

Conclusions: TMZ and nicorandil exerted similar protective effect on renal function by decreasing SCr level and CIN incidence after PCI. The efficacy of TMZ combined with nicorandil on renal protection was greater than TMZ or nicorandil alone.

This content is currently on FREE ACCESS, enjoy another 101 days of free consultation

 



Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are